Another Activist Investor Joins Calls For GSK Leadership Review

Bluebell Capital Has Already Ousted One CEO

 
• By Andrew McConaghie
  
GSK
The company's share price has underperformed in recent years, and its UK rival AstraZeneca now has a market cap nearly double GSK's £70bn.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip